Pharma News, 2024

The decision makes available in the U.S. a gene therapy GSK first began working on more than a decade ago.

As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a market firmly controlled by Novartis.  

The US Food and Drug Administration (FDA) has approved BeiGene’s TEVIMBRA (tislelizumab-jsgr) for the treatment of adults with unresectable or metastatic oesophageal squamous cell ca...

March is Myeloma Awareness Month. Multiple myeloma is a blood cancer that most often occurs in people over age 45. It's the second-most common blood cancer and the most common blood cancer in Blac...

AstraZeneca has signed a definitive agreement to acquire Amolyt Pharma, which specialises in therapies for rare endocrine diseases, in a deal worth $1.05bn.

The scientist of the Faculty of Medicine of the University of Malaga José Luis Royo has coordinated a study that summarizes eight years of research and brings together 100 multidisciplinary speci...

SHENZHEN, China -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oncolytic virus product MVR-T3011 IT (intratumoral...

Treating acute lymphoblastic leukaemia cells with the drug CX-5461 disrupts the nucleolar ribosome machinery shown by the fibrillarin protein (green) in the nucleus (blue) that stimu...

Regeneron Pharmaceuticals has announced that its Praluent (alirocumab) injection has received extended approval from the US Food and Drug Administration (FDA) to include paediatric pat...

In a worldwide first-of-its-kind study published in the journal Nature Communications this week, a team of scientists from Children's Medical Research Institute (CMRI)

Megablockbuster Keytruda was last year's best-selling drug with more than $25 billion in sales. (Merck & Co.)

After a few holdups, Swiss skincare company Galderma is finally going public in a highly anticipated market debut that could make for one of Europe’s largest listings this year.